Asociación de la hipertensión arterial y del tratamiento antihipertensivo en pacientes con COVID-19

Guillermo Alejandro Herrera Horta, Zurelys Gutiérrez García

Texto completo:

HTML PDF
Imagen de portada

Resumen

Una preocupación se suscitó en la comunidad científica durante la COVID-19, por saber si la Hipertensión Arterial o el tratamiento antihipertensivo, podrían influir en la mortalidad de estos pacientes. El objetivo de esta investigacion fue describir la asociación de la Hipertensión Arterialy del tratamiento antihipertensivo en pacientes con COVID-19. Se revisaron 51 artículos en las bases de datos Pubmed, Medline y SciELO, utilizando el buscador Google Académicocon los descriptoresSARS-CoV 2; Hipertensión; COVID-19, utilizándose 35 citas.La Hipertensión Arteriales la comorbilidad más frecuente en el paciente COVID-19. La unión de SARS-CoV-2 a las células se da por la unión de la proteína S al receptor de la Enzima Convertidora de Angiotensina 2. En la bibliografía revisada se confirma que los pacientes hipertensos tienen una peor evolución durante la COVID-19y no se muestran evidencias científicassobre la suspensión del tratamiento antihipertensivo en pacientes hipertensos con COVID-19.

Palabras clave: COVID-19; Hipertensión; SARS-CoV 2


Referencias

OMS. Foco Técnico: Investigaciones epidemiológicas y clínicas precoces sobre la COVID-19 para una respuesta de salud pública. Ginebra: OMS; 2019 [citado 05/05/2020]. Disponible en: https://www.who.int/docs/default-source/coronaviruse/200223-early-investigations-one-pager-v2-spanish.pdf?sfvrsn=8aa0856_14

Li Q, Guan X, Wu P, Wang X, Zhou L, Tonget Y, et al. Early transmission dynamics in Wuhan China, of novel coronavirus infected pneumonia. N Engl J Med. 2020[citado 08/08/2020];382(13):1199-1207. Disponible en:

https://www.nejm.org/doi/full/10.1056/NEJMOa2001316

Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J HospInfec. 2020 [citado 04/06/2020]; 104(3):246-51. Disponible en:

https://www.sciencedirect.com/science/article/abs/pii/S0195670120300463

Moreno Montoya J. El desafío de comunicar y controlar la epidemia por coronavirus. Biomédica.2020 [citado 23/04/2020]; 40(1):11-3. Disponible en:

http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-41572020000100011&lng=en

Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nature Medicine .2020 [citado 24/04/2020]; 26:450–2. Disponible en:

https://www.nature.com/articles/s41591-020-0820-9

Cui J, Li F, Li Shi Z. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol .2019 [citado 24/04/2020];17(3):181-192. Disponible en:

https://www.nature.com/articles/s41579-018-0118-9

Diao B, Feng Z, Wang C, Wang H, Liu L, Wang C, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nature Commun. 2021 [citado 24/04/2020];12(2506): 1-17. Disponible en:

https://www.nature.com/articles/s41467-021-22781-1

Rozman C. Farreras Rozman Medicina Interna.18a ed. México: McGraw-Hill Interamericana; 2016.p. 32-37.

Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020[citado 12/01/2020]; 5(7):802-10. Disponible en:

https://jamanetwork.com/journals/jamacardiology/article-abstract/2763524

Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P. SARS-CoV2: Should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?. Eur Heart J.2020[citado 09/01/2021]; 41(19): 1801-1803. Disponible en:

https://watermark.silverchair.com/ehaa235.pdf

Bavishi C, Maddox TM, Messerli FH. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. JAMA Cardiol. 2020[citado 18/08/2021]; 5(7):745-747. Disponible en: https://jamanetwork.com/journals/jamacardiology/article-abstract/2764299

Rodilla E,Saura A, Jiménez I,Mendizábal A, Pineda Cantero A, Lorenzo Hernández E, et al. Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19.J Clin Med.2020 [citado 02/08/2020];9(10):3136.Disponible en:

https://www.mdpi.com/2077-0383/9/10/3136

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.2020 [citado 23/03/2020]; 395(10229):1038. Disponible en:

https://www.sciencedirect.com/science/article/pii/S0140673620305663

Azarkish M, Far VL, Eslami M, Mollazadeh R. Transient complete heart block in a patient with critical COVID-19. Eur Heart J.2020 [citado 01/07/2020]; 4(1):2130-2131. Disponible en: https://academic.oup.com/eurheartj/article/41/22/2131/5819799?login=true

Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: At present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020 [citado 24/02/2021]; 75(6): 1382-13825. Disponible en:

https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.120.15082

Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yang YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy [Internet]. 2020 [citado 02/12/2020]; 75(7):1730-41. Disponible en:

https://onlinelibrary.wiley.com/doi/full/10.1111/all.14238

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med [Internet]. 2020 [citado 23/03/2020];180(7):934-43. Disponible en:

https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2763184

Li Q, Guan X, Wu P, Wang X, Zhou L, Tonget Y, et al. Early transmission dynamics in Wuhan China, of novel coronavirus infected pneumonia. N Engl J Med.2020;382(13):1199-1207.

Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virology. 2020 [citado 21/04/2020];94(7).Disponible en: https://journals.asm.org/doi/full/10.1128/JVI.00127-20

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020[citado 14/08/2020]; 94:91-5.Disponible en:

http://www.medicinainterna.net.pe/sites/default/files/Covid-19%20Comorbilidades.pdf

Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in COVID-19.BMJ. 2020;369:1313.

Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus disease 2019 (COVID-19): Do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect?. J Am Heart Assoc.2020 [citado 11/01/2020]; 9(7): e016509. Disponible en:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428596/

Hoffmann M, Kleine Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell.2020 [citado 26/01/2021];181(2):271-280. Disponible en:

https://www.sciencedirect.com/science/article/pii/S0092867420302294

AlGhatrif M, Cingolani O, Lakatta EG. The dilemma of coronavirus disease 2019, aging, and cardiovascular disease: Insights from cardiovascular aging science. JAMA Cardiol. 2020 [citado 07/05/2021];5(7):747-748. Disponible en:

https://jamanetwork.com/journals/jamacardiology/article-abstract/2764300

Meng J, Xiao G, Zhang J, He X, Ou M, Bi J. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect.2020 [citado 25/08/2021];9(1):757-760.Disponible en:

https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1746200

Flacco ME, Acuti Martellucci C, Bravi F, Parruti G, Cappadona R, Mascitelli A, et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart.2020;106(19):1519-1524.

Chao G, Yue C, Kan Z, Lei Z, Yao Z, Xijing Z, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J.2020 [citado 22/05/2021]; 41(22):2058-2066. Disponible en:

https://academic.oup.com/eurheartj/article/41/22/2058/5851436?login=true

Giralt Herrera A, Rojas Velázquez JM, Leiva Enríquez J. Relación entre COVID-19 e Hipertensión Arterial. Rev Haban Cienc Méd. 2020 [citado 22/05/2021]; 19(2): 172-175. Disponible en:

http://scielo.sld.cu/scielo.php?pid=S1729-519X2020000200004&script=sci_arttext&tlng=en

Chen J, Jiang Q, Xia X, Kangping L, Zhengqing Y, Wanyu T, et al.Individual Variation of the SARS-CoV2 Receptor ACE2 Gene Expression and Regulation. Aging Cell. 2020[citado 22/04/2021];19(7): e13168. Disponible en:

https://onlinelibrary.wiley.com/doi/full/10.1111/acel.13168

Kuba K, Imai Y, Rao S, Hong G, Feng G, Bin G, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med.2005 [citado 14/03/2020]; 11:875-9. Disponible en: https://www.nature.com/articles/nm1267

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?.Lancet Respir Med.2020 [citado 23/03/2020]; 8(4):e21.Disponible en:

https://id.elsevier.com/ACW/?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com

Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature.2020 [citado 28/02/2020];426(6965):450-4. Disponible en: https://www.nature.com/articles/nature02145

Danser AJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon Renin-Angiotensin system blockers. Hypertension. 2020 [citado 24/04/2020]; 75(6):1382-5. Disponible en:

https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.120.15082

Whelton PK, Carey RM,Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/ AHA/ AAPA/ ABC/ ACPM/ AGS/ APhA/ ASH/ ASPC/ NMA/ PCNA. Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71(6):1269-1324

Enlaces refback

  • No hay ningún enlace refback.

Comentarios sobre este artículo

Ver todos los comentarios
 |  Añadir comentario

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.